Johnson Aishwarya M, Ou Zhen-Yi Andy, Gordon Richard, Saminathan Hariharan
Department of Veterinary Medicine, College of Food and Agriculture, United Arab Emirates University, Al Ain, UAE.
Translational Neuroscience Laboratory, UQ Centre for Clinical Research, The University of Queensland, Australia; School of Biomedical Sciences, University of Queensland, Australia.
Int J Biochem Cell Biol. 2022 Jan;142:106113. doi: 10.1016/j.biocel.2021.106113. Epub 2021 Nov 2.
Inflammasomes are multi-protein complexes expressed in immune cells that function as intracellular sensors of environmental, metabolic and cellular stress. Inflammasome activation in the brain, has been shown to drive neuropathology and disease progression by multiple mechanisms, making it one of the most attractive therapeutic targets for disease modification in Parkinson's Disease (PD). Extensive inflammasome activation is evident in the brains of people with PD at the sites of dopaminergic degeneration and synuclein aggregation. While substantial progress has been made on validating inflammasome activation as a therapeutic target for PD, the mechanisms by which inflammasome activation is triggered and sustained over the disease course remain poorly understood. A growing body of evidence point to environmental and occupational chemical exposures as possible triggers of inflammasome activation in PD. The involvement of the gastrointestinal system and gut microbiota in PD pathophysiology is beginning to be elucidated, especially the profound link between gut dysbiosis and immune activation. While large cohort studies confirmed specific changes in the gut microbiota in PD patients compared to age-matched healthy controls, recent research suggest that synuclein pathology could be initiated in the gastrointestinal tract. In this review, we present a summarized perspective on current understanding on inflammasome activation and the gut-brain-axis link during PD pathophysiology. We discuss multiple environmental toxicants that are implicated as the etiological agents in causing idiopathic PD and their mechanistic underpinnings during neuroinflammatory events. We additionally present future directions that needs to address the research questions related to the gut-microbiome-brain mechanisms in PD.
炎性小体是在免疫细胞中表达的多蛋白复合物,作为环境、代谢和细胞应激的细胞内传感器发挥作用。已表明大脑中的炎性小体激活通过多种机制驱动神经病理学和疾病进展,使其成为帕金森病(PD)中最具吸引力的疾病修饰治疗靶点之一。在多巴胺能神经元变性和α-突触核蛋白聚集部位的帕金森病患者大脑中,广泛的炎性小体激活是明显的。虽然在将炎性小体激活作为帕金森病的治疗靶点方面已经取得了实质性进展,但在疾病过程中炎性小体激活被触发和持续的机制仍知之甚少。越来越多的证据表明,环境和职业化学暴露可能是帕金森病中炎性小体激活的触发因素。胃肠道系统和肠道微生物群在帕金森病病理生理学中的作用开始得到阐明,特别是肠道微生物群失调与免疫激活之间的深刻联系。虽然大型队列研究证实了与年龄匹配的健康对照相比,帕金森病患者肠道微生物群有特定变化,但最近的研究表明,α-突触核蛋白病理学可能始于胃肠道。在这篇综述中,我们就帕金森病病理生理学过程中炎性小体激活和肠-脑轴联系的当前理解提出一个总结性观点。我们讨论了多种被认为是导致特发性帕金森病的病因的环境毒物及其在神经炎症事件中的作用机制。我们还提出了未来的方向,需要解决与帕金森病中肠道微生物群-脑机制相关的研究问题。